Skip to content

IBS-C Questionnaire Study

Evaluation of the Simplified Diagnosis Tool for Chinese IBS-C (Irritable Bowel Syndrome With Constipation) Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04968652
Enrollment
300
Registered
2021-07-20
Start date
2021-11-01
Completion date
2022-10-28
Last updated
2023-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Constipation, Irritable Bowel Syndrome With Constipation

Keywords

IBS-C; functional constipation; diagnosis, questionnaire

Brief summary

The study is a multi-centre, observational study which enrolls 150 IBS-C patients and 150 non-IBS-C patients in China.

Detailed description

The potential study subject will be identified by the investigators by face-to-face visit, and there will be only 1 visit in this study. Every patient will complete both ROME IV and the Simplified Diagnosis Tool during the visit, and in the same day. The study will collect results of the ROME IV and the Simplified Diagnosis Tool. Sensitivity and specificity of simplified diagnosis methodology compared with ROME IV will be analysed after all the data has been collected.

Interventions

None listed

Sponsors

First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Third Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
Ruijin Hospital
CollaboratorOTHER
The First Affiliated Hospital of Nanchang University
CollaboratorOTHER
Henan Provincial People's Hospital
CollaboratorOTHER
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
CollaboratorOTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CollaboratorOTHER
Peking University First Hospital
CollaboratorOTHER
The First Affiliated Hospital of Anhui Medical University
CollaboratorOTHER
Shengjing Hospital
CollaboratorOTHER
AstraZeneca
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Group 1 (IBS-C) * ≥18 years old * Decrease of frequency of bowel movement (\<3 time per week), change of stool consistency (stool that is hard and difficult to pass, Bristol Types 1 to 3), or other 'constipation symptoms' judged by investigators. * With abdominal symptoms such as abdominal pain, bloating, and abdominal discomfort, or other 'constipation symptoms' judged by investigators. * Result of ROME VI marked as 'IBS-C'. Group 2 (non-IBS-C) * ≥18 years old * Decrease of frequency of bowel movement (\<3 time per week), change of stool consistency (stool that is hard and difficult to pass, Bristol Types 1 to 3), or other 'constipation symptoms' judged by investigators. * With abdominal symptoms such as abdominal pain, bloating, and abdominal discomfort, or other 'constipation symptoms' judged by investigators. * Result of ROME VI marked as 'Non IBS-C'.

Exclusion criteria

* Individuals with a cognitive condition and unable to finish the questionnaire. * Individuals have an acute or chronic non-GI condition that can be associated with constipation; e.g., central nervous system cause (Parkinson's disease, spinal cord injury, and multiple sclerosis), pseudo-obstruction, colonic inertia, megacolon, megarectum, bowel obstruction, descending perineum syndrome, solitary rectal ulcer syndrome, systemic sclerosis. * Individuals who had been diagnosed with the following organic health problems likely to affect GI symptoms: * Inflammatory bowel disease (Crohn's disease or ulcerative colitis) * cancer anywhere in the GI tract or current infection of the GI tract. * Pelvic floor dysfunction. (i.e., disease that is not adequately treated or stable with therapy.) * Any history of colon surgeries. * Individuals who participate in any interventional study currently. * Not suitable for the study judged by investigators.

Design outcomes

Primary

MeasureTime frameDescription
the sensitivity and specificity of the Simplified Diagnosis Tool for Chinese IBS-C patients14 monthsSensitivity (%)=(number of patients judged as IBS-C based on both the Simplified Diagnosis Tool and the ROME IV)/( number of patients judged as IBS-C based on ROME IV) ×100% Specificity (%)=(number of patients judged as non-IBS-C based on both the Simplified Diagnosis Tool and ROME IV)/( number of patients judged as non-IBS-C based on The ROME IV) ×100%

Secondary

MeasureTime frameDescription
the accuracy of the Simplified Diagnosis Tool14 monthAccuracy (%)=(number of patients judged as IBS-C based on both the Simplified Diagnosis Tool and The ROME IV + number of patients judged as non-IBS-C based on both Simplified Diagnosis Tool and The ROME IV) / (total number of patients in the FAS) ×100%
the Kappa coefficient of the Simplified Diagnosis Tool14 monthsThe Kappa coefficient will be calculated according to the following formula: Kappa coefficient=(P0-Pe)/(1-Pe)
the positive predictive value, and negative predictive value of the Simplified Diagnosis Tool14 monthsPositive predictive value (%)=(number of patients judged as IBS-C based on both Simplified Diagnosis Tool and The ROME IV)/(number of patients judged as IBS-C based on Simplified Diagnosis Tool) ×100% Negative predictive value (%)=(number of patients judged as non-IBS-C based on both Simplified Diagnosis Tool and The ROME IV)/( number of patients judged as non-IBS-C based on Simplified Diagnosis Tool) ×100%

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026